In Search of Targeted Therapies for Childhood Cancer by Mackall, Crystal L.
www.frontiersin.org  July 2011  | Volume 1  |  Article 18  |  1
Specialty Grand challenGe article
published: 20 July 2011
doi: 10.3389/fonc.2011.00018
In search of targeted therapies for childhood cancer
Crystal L. Mackall*
Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA
*Correspondence: cm35c@nih.gov
Progress made in the battle to cure child-
hood cancer is one of the great success 
stories of modern medicine. Some diseases 
that were universally fatal 50 years ago, such 
as pediatric acute lymphoblastic leukemia, 
can now be cured in approximately 80% of 
patients (Margolin et al., 2011). Current 
standard therapies for children with Wilm’s 
tumor, thyroid cancer, Hodgkin disease, 
and Burkitt’s lymphoma cure more 90% of 
patients and overall 10-year. survival rates 
for children treated for cancer in developed 
countries is approximately 75% (Scheurer 
et al., 2011). Despite these successes, there 
are substantial limits to our progress. 
Equivalent gains have not occurred across 
all histologies, disease stages, epidemiologic 
subgroups and global populations, and cure 
is associated with substantial long-term 
morbidity and increased mortality.
Diseases such as diffuse intrinsic pontine 
glioma (DIPG) vividly illustrate the limits 
of progress against childhood cancer. No 
significant improvements in outcome for 
patients with DIPG have occurred despite 
years of clinical and basic research, and 
more than 90% of patients with DIPG die 
within 2 years of diagnosis, despite radia-
tion therapy, which is the only standard 
treatment available (Hargrave et al., 2006). 
Survival rates remain <30% for patients 
with metastatic pediatric sarcomas, and 
these are unchanged from those observed 
in the 1970s, despite the fact that pro-
gressive improvements in survival have 
occurred in patients with the same his-
tologies, but without clinical evidence for 
metastases (Raney et al., 2001; DuBois 
and Grier, 2009; Ladenstein et al., 2010). 
Modest progress has been made against 
high-risk neuroblastoma, acute myeloid 
leukemia, and non-DIPG pediatric brain 
tumors, but cure rates still approximate 
50% for these diseases. Furthermore, while 
outcomes for most pediatric cancers have 
clearly improved over the last 50 years, the 
rate of progress in the last decade has slowed 
overall, and new therapies that are likely to 
substantially improve cure rates in the next 
5–10 years are not readily apparent.
Progress against childhood cancer has 
also been unbalanced with regard to patient 
age, ethnicity, and race. For a variety of 
childhood cancers, infants, adolescents, and 
young adults have not experienced the same 
increase in survival rates that have been 
observed for children (Scheurer et al., 2011). 
In some diseases, such as rhabdomyosar-
coma and acute lymphoblastic leukemia, 
at least some of the age related differences 
in survival are largely driven by differences 
in tumor subtype, such that less treat-
ment responsive tumors occur in infants 
and older age groups (Pieters, 2009; Perez 
et al., 2011; Tricoli et al., 2011). However for 
Ewing’s sarcoma, outcomes are consistently 
lower for adolescents and adults, yet there is 
no evidence that the biology of the tumor 
changes with age, raising the prospect that 
the differences in survival rates may relate 
to host or treatment factors (Maki, 2008). 
With regard to ethnicity and race, several 
multicenter studies have demonstrated that 
Hispanic and black children with acute 
lymphoblastic leukemia and acute myeloid 
leukemia have lower survival outcomes 
compared to white non-Hispanic and Asian 
children (Pollock et al., 2000; Bhatia et al., 
2002; Children’s Oncology Group et al., 
2006; Lange et al., 2008; Bhatia, 2011), and 
lower survival rates are also observed in 
black children with Hodgkin disease com-
pared to white children (Percy et al., 1999). 
There is evidence to suggest that inferior 
outcomes in these populations may reflect 
a combination of factors, including differ-
ences in disease subtype prevalence (Aldrich 
et al., 2006; Harvey et al., 2010), pharma-
cogenomic differences that effect tolerance 
to therapy (Hon et al., 1999), availability 
of marrow transplant donors (Lange et al., 
2008) as well as access to care, and this is an 
important area for future study.
The greatest imbalance in outcomes 
relates to the treatment of childhood can-
cer in the developing world. Worldwide, 
it is estimated that 160,000 children are 
diagnosed with cancer each year, and that 
approximately 90,000 children die of cancer 
each year. As noted above, approximately 
75% of children with cancer in developed 
countries are cured of their disease, whereas 
cure rates are estimated to be 10–20% in the 
world’s poorest countries and many chil-
dren are not even treated for their disease 
due to inadequate access to care. Thus, the 
compelling survival rates from developed 
countries belie the global toll of childhood 
cancer.
Much of the improved survival accom-
plished in pediatric oncology has resulted 
from the administration of dose intensive 
cytotoxic chemotherapy and radiotherapy, 
both of which induce substantial long-term 
late effects. The Children’s Cancer Survivor 
Study, which evaluated late effects in more 
than 10,000 US children treated for cancer 
between 1970 and 1986, demonstrated that 
two-thirds of all childhood cancer survivors 
suffer from a chronic condition and more 
than 40% are estimated to suffer a severe, 
disabling, or life-threatening condition 
30 years after their diagnosis (Oeffinger 
et al., 2006). Similar results were seen in a 
large European study (Geenen et al., 2007), 
which also demonstrated that radiotherapy 
is a major factor increasing the severity of 
late effects. In general, patients cured of 
Hodgkin disease, brain tumors, and bone 
tumors appear to be at greatest risk for late 
effects due to cancer therapy (Oeffinger 
et al., 2006; Geenen et al., 2007).
Thus, while the “cup is half-full” per-
spective on childhood cancer is often 
emphasized, plateaus in progress, unbal-
anced outcomes across diseases and patient 
groups, and alarming rates of late effects 
emphasize a pressing need for new targeted 
therapies, which are less toxic and more 
effective. Progress in the development of 
targeted therapies for childhood cancer has 
lagged behind that in adult oncology. The 
reasons for this are manifold, including the 
fact that large financial markets and the lack 
of other effective therapies for many adult 
cancers energized the search early for tar-
geted therapies for adult cancers. Despite 
the dramatic increases in the numbers of 
targeted therapies approved for adult can-
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(Figure 1, Pathway #2). For example, the 
IGF1 signaling pathway seems to be a sig-
nificant axis for targeting Ewing’s sarcoma, 
with an overall 10–15% objective response 
rate as a single agent in patients with refrac-
tory disease (Patel et al., 2009). While it is 
unclear if this response rate as a single agent 
is sufficient for FDA approval, multiagent 
therapies could be effective. However, 
it remains unclear whether these agents 
will remain available for study in pediat-
ric oncology as commercial development 
has been abandoned by many companies, 
due to insufficient activity in adult cancers. 
NOTCH is mutated in approximately 50% 
of T-cell ALL, but NOTCH inhibitor stud-
ies in adult cancer have not demonstrated 
dramatic efficacy as yet, and pediatric stud-
ies are ongoing. Flt3 inhibitors have been 
studied in Flt3 mutant adult AML and 
results thus far have not confirmed sig-
nificant activity (Levis et al., 2011), raising 
the possibility that pediatric studies may 
yield negative results as well or that these 
agents will not be made available for study 
in children.
In some cases, negative results in adult 
cancers could prevent unnecessary studies 
in children with cancer, where patient num-
bers are small and studies must be highly 
prioritized. However, it seems likely that 
there may be situations where the possibil-
ity remains that a targeted agent is active 
against a pediatric cancer but   failure to 
2009). Similarly, promising results have 
been seen with JAK2 inhibitors in myelo-
proliferative diseases in adults (Quintas-
Cardama et al., 2011). JAK2 was recently 
identified as a mutated oncogene in high-
risk and Down’s syndrome associated acute 
lymphoblastic leukemias (Bercovich et al., 
2008; Gaikwad et al., 2009; Mullighan et al., 
2009) and thus studies with JAK2 inhibitors 
in JAK2 mutated pediatric ALL are anx-
iously awaited. Activating mutations in 
BRAF are present in approximately 50–60% 
of adults with melanoma and treatment 
with BRAF inhibitors has yielded impres-
sive responses (Poulikakos and Rosen, 
2011). Several pediatric tumors including 
melanoma, juvenile pilocytic astrocytoma, 
and other low grade gliomas in pediatrics 
demonstrate BRAF mutations which may 
be amenable to the agents currently under 
study (Dougherty et al., 2010; Schindler 
et al., 2011). Drugs such as these, which 
are being successfully developed for adult 
cancers, and which are also active in pedi-
atric cancer represent the “low hanging 
fruit,” and should be studied in children 
with cancers bearing the targets as rapidly 
as possible.
A second, and more challenging, model 
occurs when targeted agents show insuf-
ficient promise in adult cancers to merit 
further commercial development, yet 
preclinical or early clinical studies sug-
gest potential activity in pediatric cancer 
of these agents have demonstrated activity 
in childhood cancer (Table 1) and these tar-
get a miniscule fraction of children diag-
nosed with cancer annually. For example, 
bcr-abl inhibitors are effective as single 
agents and adjuncts in pediatric CML and 
t(9;22) ALL respectively, but these diseases 
are quite rare in pediatrics, representing 
<5% of all pediatric leukemia. Thus, in 
2011, most children with cancer continue 
to receive treatment regimens based upon 
dose intensive cytotoxics, rather than tar-
geted therapies.
A variety of exciting targets have been 
identified in common pediatric tumors 
and progress is underway to translate 
these insights into clinical benefit. Among 
the most promising are drugs that have 
activity in adult tumors and also target 
oncogenes believed to be important for 
pediatric tumors (see Figure 1, Pathway 
#1). For example, drugs targeting anaplas-
tic lymphoma kinase, have shown signifi-
cant activity in non-small cell lung cancer, 
and these also appear to be active in t(2;5) 
anaplastic large cell lymphomas, which 
comprise approximately 15–20% of child-
hood lymphomas (Gambacorti-Passerini 
et al., 2011). ALK inhibitors may also be 
active in the rare familial neuroblastoma 
with mutated ALK (Janoueix-Lerosey et al., 
2008; Mosse et al., 2008), and/or in neuro-
blastomas and other pediatric solid tumors 
with ALK amplification (Passoni et al., 
Table 1 | FDA approved targeted agents with demonstrated activity in pediatric cancers.
Target  FDA approved agent(s)  Disease activity
Adult cancers Pediatric cancers
Bcr-abl Imatinib; dasatinib; nilotinib CML, t(9;22) ALL CML (Millot et al., 2006), t(9;22) ALL (Schultz et al., 2009)
c-Kit Imatinib c-Kit mutated gastrointestinal stroma 
tumor (GIST)*, systemic mastocytosis
Systemic mastocytosis (Hoffmann et al., 2008)
CD20 Rituximab; ofatumumab; 
tositumomab; 131I-tositumomab; 
ibritumomab
Non-Hodgkin lymphoma CD20+ B-cell non-Hodgkin lymphoma including Burkitt 
lymphoma, DLBCL, and some ALL (Attias and Weitzman, 
2008; Reiter et al., 2009; Meinhardt et al., 2010)
PDGFR Imatinib Dermatofibrosarcoma protuberans 
(DFSP)




Tretinoin; alitretinoin; isotretinoin AIDS-related Kaposi sarcoma; acute 
promyelocytic leukemia
Acute promyelocytic leukemia; neuroblastoma
CD52 Alemtuzumab Chronic lymphocytic leukemia (CLL); 
cutaneous T cell lymphoma (CTCL); T-cell 
lymphoma
ALL (Angiolillo et al., 2009)
RET Vandetanib Medullary thyroid carcinoma Medullary thyroid carcinoma (Fox et al., 2009)
*Pediatric GIST does not express mutated c-kit, and imatinib has not shown activity in pediatric GIST (Pappo and Janeway, 2009; Janeway et al., 2011).www.frontiersin.org  July 2011  | Volume 1  |  Article 18  |  3
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emphasized. The academic community 
will drive the science that identifies targets 
that childhood cancers share in common 
with adult tumors as well as in identifying 
unique targets for pediatric cancers. The 
academic community will prioritize agents 
for study and cooperate to undertake the 
most informative, yet most efficient stud-
ies of these targeted agents to minimize 
the numbers of patients needed to make 
valid conclusions. Frontiers in Pediatric 
Oncology seeks to provide a forum for 
rapid dissemination of basic, preclinical, 
and clinical studies as well as policy discus-
sions aimed at hastening the pace of devel-
opment of targeted therapies for childhood 
cancer. The explosion in biologic insights 
and technology that the entire biomedical 
research community has witnessed over 
the last 25 years can and must be leveraged 
to improve outcomes for all children with 
cancer and to reduce the cost of cure. It is 
up to those of us committed to the field of 
pediatric oncology to make this happen.
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